Lunresertib is a small molecule commercialized by Repare Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 5 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lunresertib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lunresertib is expected to reach an annual total of $30 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Lunresertib Overview
Repare Therapeutics Overview
Repare Therapeutics is a clinical-stage precision oncology company. Its products include lunresertib, a PKMYT1 inhibitor, camonsertib, an ATR inhibitor, RP-1664, a PLK4 inhibitor, and RP-3467, a Polo ATPase inhibitor. Repare Therapeutic utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company operates under the brand SNIPRx. It operates in the US and Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.
The company reported revenues of (US Dollars) US$51.1 million for the fiscal year ended December 2023 (FY2023), a decrease of 61.2% over FY2022. The operating loss of the company was US$116.2 million in FY2023, compared to an operating loss of US$19.8 million in FY2022. The net loss of the company was US$93.8 million in FY2023, compared to a net loss of US$29.1 million in FY2022.
The company reported revenues of US$52.4 million for the first quarter ended March 2024, compared to a revenue of US$13.1 million the previous quarter.
For a complete picture of Lunresertib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.